Panel discussion  - Redefining the speed of innovation

Information

  •  Industry actors and regulators managed to speed the development and approval time of the COVID-19 vaccine. Is it possible – and desirable – to maintain this momentum under more normal circumstances? Do we have the right priorities when it comes which pharma products are fast-tracked?     
  • Should the industry and regulators rethink how we approach clinical trials and what would that entail? What impact would new technologies play in that regard?   
  • What has the pandemic taught us about using Real World Data (RWD)? Does it hold the potential to revolutionize the way new drugs are tout on the market?  
  • How much does speed rely on stronger cooperation between researchers, public and industry actors? Can HERA find the right formula?   
LillyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, visit www.lilly.com and check out our European site at www.lillyeu.com .

Registered attendees

FB
Francesco Bordone
European Commission

Log in